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Alzheimer’s disease (AD), the most common form of de-
mentia, creates a vast social and economic burden on society
and takes a heavy emotional toll on patients, caregivers, and
families [1]. With the prevalence of dementia expected to
exceed 115 million worldwide by 2050, it is noteworthy
that relatively little progress has been made in developing
and introducing medicines that may slow or halt the progres-
sion of AD or in establishing integrated systems to manage
patient care [2]. Additionally, before 2007, the diagnostic
guidelines for AD dementia had remained unchanged for
23 years [3]. Recent scientific advances have driven the
advancement of new clinical diagnostic criteria for AD de-
mentia and mild cognitive impairment (MCI) due to AD,
together with a research agenda for preclinical AD [4–8].
These diagnostic criteria should yield a more accurate
assessment of AD prevalence and increase our
understanding of its etiology, pathophysiology, and
progression.
In 2012, the Alzheimer’s Disease Working Group
(ADWG) was assembled as a multicountry multistake-
holder forum for public- and private-sector stakeholders
to address the challenges of AD and identify potential solu-
tions that could benefit European health systems [9]. Over
the course of three in-person meetings and numerous group
teleconferences, the ADWG integrated international per-
spectives across the varied elements of health and social
care that touch AD patients and their carers. ADWG partic-
ipants and guests included general practitioners, clinical
specialists, patient/policy advocates, medicine and diag-
nostic developers, health economists, social care represen-
tatives, regulators, health technology assessors (HTAs),
and payers. All participants acknowledged that the scienti-
fic and economic challenges associated with AD are simply
too great for stakeholders to address solely from within
their own silos.
The ADWG was assembled and independently led by
Tapestry Networks and was financially underwritten by
Bristol-Myers Squibb, GE Healthcare, and Johnson &
Johnson. Tapestry Networks endeavored to include as
many competing stakeholder viewpoints as possible in
the ADWG while maintaining an intimate size (w20–25
participants) to foster engaged discussion and active
development of new approaches. The ADWG had contin-
uous engagement from the same participants throughout
the yearlong multimeeting process. Stakeholder represen-
tation was balanced to ensure strong public-sector pres-ence and cross-sector expertise including: 6 to 8
regulators, HTAs, and payers; 6 to 8 subject matter ex-
perts; 2 to 3 patient and policy advocates; and 5 to 6 in-
dustry representatives. Nonindustry participants or their
institutions received an honorarium and/or were reim-
bursed by Tapestry Networks for travel expenses to the
extent it was in accordance with the mandates of the par-
ticipant’s institution and not incompatible with national
laws or professional bodies of which the participant was
a member.
All ADWG participants co-shaped the agenda and had an
equal voice in the discussion. The focus was generally on
European countries’ health-care challenges in AD with the
acknowledgment that the science and challenges in AD
were global. Given the size parameters, the ADWG did
have limitations. For example, the ADWG did not have
direct patient participation. Instead, to integrate the broad
consortia of advocacy across AD and ensure strong technical
knowledge, the ADWG had representation from Alz-
heimer’s Disease International and the Alzheimer’s Society
in the United Kingdom. Guest speakers were brought in to
challenge viewpoints or balance overrepresented view-
points. ADWG meeting summaries with full lists of partici-
pants and guests are freely available via Tapestry Networks’
Web site.
In this perspective, we present a set of recommenda-
tions that highlight key consensus areas and gaps that
need to be bridged across stakeholder groups to make
progress in the fight against AD. The recommendations
are an attempt to faithfully capture and summarize the
ADWG’s discussions, and the vast majority of ADWG
participants have contributed to the authorship of this
article. All participants, regardless of authorship, had an
opportunity to comment, and all views were integrated.
However, because a small number of participants chose
not to author or were precluded by their organizational
mandates, we note that the recommendations are those
of the individual coauthors and not the entire ADWG.
Most importantly, the authorship group accurately reflects
the broad range of stakeholder views expressed within the
ADWG meetings.
The following recommendations together encompass
the view that stakeholders must work together to
improve the organization and delivery of existing treat-
ments and simultaneously create a more receptive envi-
ronment for the development and use of future
medicines Table 1.
Table 1
Key recommendations
Key recommendations for improving the organization and delivery of AD
care
 In the face of limited resources, health-care systems must make
specific choices regarding the patient populations to be diagnosed
and treated. Although routine screening of the general population is
not warranted, there is a lack of consensus between the patient and
payer perspectives on the value of an early AD diagnosis in the
absence of a disease-modifying treatment.
 Health systems should use an evidence-based integrated care
standard for AD. Although regional differences exist, all care
standards should share the following core principles: (1) patients
and their families should be at the center of the care standard, (2) the
care standard must accept patients at all stages of AD, (3) the
success of any care standard needs to be tied to its ability to deliver
better AD health outcomes, (4) the care standard should be designed
to engage symptomatic patients as early as possible, and (5) the care
standard should be defined in terms of functions to be delivered
rather than elucidating the role of a particular practitioner.
Key recommendations for improving the development of new AD
treatments
 Increased collaboration between and across public and private
institutions is necessary to enhance research on the etiology and
progression of AD.
 Reimbursement end points need to be agreed on and validated. All
stakeholders have a role in collecting this evidence.
 Innovative business models or agreements should be used to spur
the development of new AD medicines.
Abbreviation: AD, Alzheimer’ disease.
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and delivery of AD care
2.1. In the face of limited resources, health-care systems
must make specific choices regarding the patient
populations to be diagnosed and treated. Although routine
screening of the general population is not warranted, there
is a lack of consensus between the patient and payer
perspectives on the value of an early AD diagnosis in the
absence of a disease-modifying treatment
Researchers, clinical specialists, and diagnostic devel-
opers have made significant progress in the identification
and measurement of early biological markers of AD [10].
Potentially useful tools for making an early diagnosis
include positron emission tomography (PET) scans to mea-
sure brain amyloid and assays to measure AD biomarker
proteins in the blood and spinal fluid [11,12]. These
advanced diagnostic technologies are making important
contributions to the research and development of new AD
medicines. Additionally, appropriate use criteria for
amyloid-detecting PET radiopharmaceuticals have been
proposed jointly by the Society of Nuclear Medicine and
the Alzheimer’s Association [13]. If upcoming trials and an-
alyses of public databases confirm the validity of one or
more of these technologies as an early diagnostic tool with
a satisfactory level of sensitivity and specificity, payers
should consider coverage in the research setting. However,at this time, given the limited resources of European Union
health-care systems and the unknown magnitude of the risk
of false-positive cases, we do not endorse the use of
advanced diagnostic tools to screen the general population
for AD. Instead, health systems must decide which specific
at-risk populations to diagnose, set clear diagnostic guide-
lines, and provide education and training to frontline profes-
sionals. As described in the following, we recognize that
these explicit choices are especially challenging in a context
of disagreement over what treatments to provide.
Two contrasting viewpoints, reflecting the differing
stakeholder priorities, have emerged regarding the value of
an early AD diagnosis in the absence of a disease-
modifying treatment (DMT). Specialists and patient advo-
cates tend to support a prompt and accurate AD diagnosis,
particularly if requested by a concerned patient with credible
risk—that is, a person seeking medical advice for symptoms
indicating the potential for a serious brain disease. These
stakeholders maintain that a timely diagnosis is critical for
proper patient management and has psychological benefits
arising from relief from the burden of uncertainty. In addi-
tion, they believe that existing treatments, including non-
pharmacological treatments, can be beneficial. However,
payers, HTAs, and some primary care physicians remain
skeptical. Payers in particular would promote diagnostic
testing for AD only if it was known that this information
would change patient treatment and improve clinical out-
comes. According to this viewpoint, a predementia diag-
nosis of AD should not be reimbursed in the absence of a
specific DMT. To bridge this divide, we encourage develop-
ment of a more robust evidence base illustrating the effec-
tiveness of existing interventions, including
nonpharmacological treatments, to support the case for early
diagnosis in the absence of a DMT.
Regardless of which patients receive it, diagnostic testing
for AD will require clear guidelines and a set of simple tests
for frontline providers in community/primary care clinics. For
example, health systems should promote AD diagnostics that
show clear evidence of accuracy and precision. Additionally,
even if DMTs became available, access to diagnostic testing
would still depend on patient risk factors, including family
history, age, and lifestyle. Other considerations include symp-
toms, the stage of the disease, comorbidities, and the clinical
and cost-effectiveness of contemplated therapies. In the event
that advanced diagnostic technologies receive coverage,
referral networks may be necessary to guide patients to those
clinics with the appropriate infrastructure.
Finally, to facilitate a coordinated approach, we believe
that the AD community needs a shared set of definitions of
the different stages of AD. For example, the International
Working Group for New Research Criteria for the Diagnosis
of AD proposed a “clinicobiological” lexicon that could
serve as a common conceptual framework in the future
[5]. Education for frontline health-care providers on the
consensus definitions will be necessary before effective im-
plementation of diagnostic and treatment criteria. In
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referral, enrollment, and interpretation of clinical studies.
Additional education for general providers on advanced
diagnostic tools will be necessary if those technologies
move from the research setting into the clinic.
2.2. Health systems should use an evidence-based
integrated care standard for AD. Although regional
differences exist, all care standards should share certain
core principles
As explained in the United Kingdom’s National Demen-
tia Strategy, AD and dementia require us “to transcend exist-
ing boundaries between health and social care and the third
sector, between service providers and people with dementia
and their carers” [14]. In that spirit, the ADWG agreed on a
vision for an idealized care pathway for AD:Empowered patients and caregivers going through a
patient-centred, de-stigmatised journey of diagnosis and
treatment; who move through a co-ordinated and inte-
grated primary, specialty and social care system; a system
that is supported by appropriate infrastructure, education,
budgets and incentives for efficient and cost-effective
care [15].To realize this vision, all health systems should use an
evidence-based integrated care standard. The United
Kingdom, for example, developed its national clinical guide-
line according to the best available evidence, which included
qualitative evidence [16]. Although we acknowledge the di-
versity of systems and regional and cultural biases in the de-
livery of care, we believe that all care standards should share
the following core principles:
First, patients and their families should be at the center of
the care standard. Assigning a “navigator” to coordinate a
patient’s care would help centralize treatments, recognize
comorbidities, minimize the burden and expenses of care
handoffs, and assist in identification of community re-
sources. This navigator, or care coordinator, could be housed
in a physical location such as a memory clinic, primary care
office, or municipal center or could be accessed through an
Internet portal. Additionally, the care standard should
include clinical and social services assessments and a
referral to support groups.
Second, the care standard must accept patients at all
stages of AD. Although the hope is that all patients will enter
these pathways at the early stage, the reality is that stigma
and misconceptions will prevent many from receiving a
timely diagnosis. The types and amount of required coordi-
nated services will vary by the disease stage.
Third, the success of any care standard is tied to its ability
to deliver better AD health outcomes. Therefore, it is critical
to define those outcomes and begin to measure them rigor-
ously. Launching an integrated standard of care in a time
of strained health budgets is not possible unless the care
standard contains an explicit promise to evaluate its own
benefits. Outcome measurement needs to be built directlyinto the care standard. Although health system designers
should emphasize objective measures such as activities of
daily living, cognitive performance, delayed time to institu-
tionalization, or costs, they should also consider less tangible
patient-reported outcomes such as quality of life and care-
giver satisfaction. Wherever possible, the selected outcomes
should be standardized across health systems. Finally,
because the costs and benefits of an integrated care standard
are distributed throughout society, policy makers will need
to apply a societal viewpoint that extends beyond depart-
mental budgetary concerns.
Fourth, care standards should be designed to engage
symptomatic patients as early as possible. We believe that
care standards can further improve AD and dementia aware-
ness by framing the benefits of earlier identification as
providing options rather than confirming a dreaded suspi-
cion. Evidence-based nonpharmacological interventions
and services that benefit patients but do not require a formal
AD diagnosis should be applied. We recognize that many
health systems under economic pressures will not have bud-
gets to accommodate a broad adoption of validated advanced
diagnostics. Nevertheless, policymakers should consider us-
ing these tools as part of the differential diagnosis for spe-
cific sets of early stage patients and should provide access
to clinical trials when medically appropriate.
Fifth, the care standard should be defined in terms of
functions to be delivered rather than elucidating the role of
a particular practitioner. Given current economic pressures,
health-care systems should focus on providing cost-
effective integrated AD services that satisfy their quality
standards, whether delivered by specialist nurses, general
practitioners, social carers, or specialists. On a related
note, health authorities also need to consider whether exist-
ing management structures are sufficient for implementing
and operating an integrated care standard for AD.3. Key recommendations for improving the development
of new AD treatments
3.1. Increased collaboration between and across public
and private institutions is necessary to enhance research
on the etiology and progression of AD
With so many open questions regarding the underlying
causes and mechanisms of AD, the need for increased
collaboration between and across public and private institu-
tions is enormous. Although the AD field has many active
consortia, we believe that a more expansive cooperation
across public and private stakeholders will yield the most
timely and deep understanding of AD etiology and progres-
sion. ADWG discussions suggested that greater payer
involvement in these collaborations could speed the pace
of AD understanding. In particular, capitalizing on payers’
ability to track outcomes could assist in AD biomarker vali-
dation, patient stratification, and the development of longitu-
dinal studies.
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biomarkers is critical to address the biological complexity of
AD. Collaborating to test the validity and reliability of AD
biomarkers in representative clinical populations will yield
two major benefits. First, validated diagnostic biomarkers
will enable earlier diagnosis of AD and allow for more
streamlined clinical development of potential therapies.
For example, clinical trials could be designed around pa-
tients with a less advanced disease phenotype, and diag-
nostic biomarkers may allow stratification of the clinical
trial patient population. The result would be an enriched
and more cost-effective clinical trial process. Second, vali-
dated biomarkers of AD progression will help to establish
baseline comparators for clinical and cost outcomes.
To accelerate progress in diagnostic AD biomarkers, in-
dustry should build on recent efforts to expand the precom-
petitive space through sharing of raw data from clinical
trials. For example, GlaxoSmithKline has announced a
plan to allow qualified researchers open access to the anony-
mized patient-level clinical trial data for both its approved
medicines and its nonapproved investigational medicines
[17]. Regulators, too, are embracing the benefits of science
as an open enterprise. The European Medicines Agency
(EMA) announced that it does not consider submitted clin-
ical trial data to be commercially confidential and plans to
proactively publish these data as of January 1, 2014
[18,19]. A collaborative strengthening of the AD evidence
base will allow stakeholders to independently confirm
published findings, more efficiently perform meta-analyses
and genome-wide association studies, validate trial end
points and biomarkers, and ultimately stratify the patient
population into treatable subgroups. As noted previously, pa-
tient stratification should, in turn, spur more efficient and
effective clinical trials with the promise of a more rapid de-
livery of safe and innovative medicines to the public.
Regarding biomarkers of AD progression, stakeholders
must continue to work together to explore the natural course
of the disease. Although public-private partnerships such as
the Alzheimer’s Disease Neuroimaging Initiative [20] and
the Coalition Against Major Diseases [21] successfully
gather, standardize, and disseminate AD-related data to
qualified researchers free of charge, we believe that stake-
holders could accelerate the understanding of AD through
greater engagement of payers and existing outcome data.3.2. Reimbursement end points need to be agreed on and
validated. All stakeholders have a role in collecting this
evidence
During the ADWG meetings, discussion repeatedly
turned to the critical role of reimbursement in supporting
innovative AD treatments. In general, demonstrating cost-
effectiveness for approved AD drugs has been difficult,
and we anticipate DMTs to be especially difficult to value
because heterogeneous progression and the long natural
course of AD make a quick demonstration of functionalimprovement unlikely. For example, contrast these medi-
cines to oncology drugs, for which outcomes are generally
more readily assessed. These difficulties have resulted in a
great deal of confusion regarding which outcomes best
demonstrate real-world effectiveness in AD treatments to
HTAs and payers. The challenge is to model long-term out-
comes for these new treatments on the basis of short-term
data. Although some uncertainty will surely remain, stake-
holders should agree on end points that, taken together,
could provide a composite picture of long-term effective-
ness. These end points must be clinically and economically
relevant to HTAs and payers, realistic to developers, and
important to patients and carers. After selecting a set of stan-
dardized end points, stakeholders should then use innovative
tools and statistical models to validate them.
Although currently preferred reimbursement end points
vary by stakeholder group, we believe that agreement on a
suite ofmeasures to serve as primary and secondary end points
is achievable. The measures should capture both the clinical
and cost-effectiveness of the treatment at issue. In general,
HTAs and payers demonstrated a clear preference for objec-
tive end points such as functional measures or resource con-
sumption measures, whereas patient advocates placed
greater emphasis on quality-of-life metrics. Developers
emphasized that the measures must be ascertainable within
an economically viable time frame; that is, they should not
unduly erode the treatment’s period of exclusivity. Integrating
these views, the ADWG identified end points that could
demonstrate effectiveness within 2 years after the launch of
a DMT and from 2 to 5 years after the launch. This list of
end points provides one perspective on a starting point for
gauging the real-world effectiveness ofAD treatmentsTable2.
The validation of selected reimbursement end points is
another rich opportunity for multistakeholder collaboration.
In particular, public and private stakeholders should work
together to conduct and finance the long-term follow-up
necessary for end point validation. Although acknowledging
that no tool is perfect, we believe that innovative technolo-
gies and statistical/economic models should be used to track
the connection between reimbursement end points and
long-term outcomes. In particular, we support the use of
broad-scale registries, electronic medical records, and other
databases to monitor downstream outcomes. Investing in the
collection of these data ultimately will assist all stake-
holders. For example, these data could serve as baseline
comparators for a novel DMT to demonstrate cost savings
attributable to a shortening of the severe stage of AD. Alter-
natively, they could be used to anticipate expenditures asso-
ciated with the slowing of progression and lengthening of
stages of the disease.3.3. Innovative business models or agreements should be
used to spur the development of new AD medicines
Despite the immense unmet medical need, many pharma-
ceutical companies have scaled down their search for new
Table 2
Clinical effectiveness end points*
Clinical effectiveness end points, ,2 years after a launch
 Prevention/lowering of cognitive decline
 Better ADL functioning scores
 Patient autonomy/maintenance of independence
 Patient and caregiver consumption of resources (e.g., effect on
referral patterns, decreased use of psychotropics)
 Quality of life or satisfaction (patient-reported outcomes or
caregiver as a proxy)
 Biomarkers that are linked to slowing disease progression
 Safety and reduction of adverse events
Clinical effectiveness end points, 2–5 years after a launch
Same outcomes as above with the addition of the following:
 Duration of response
 Time to the next stage of disease progression such as “progression
of prodromal to dementia or from dementia to severe dementia
defined by MMSE of 10”
 Delay to nursing home/reduced rate of institutionalization, nursing
home readiness score
 Mortality/longer life
 Compliance with treatment
Abbreviations: ADL, activity of daily living; MMSE, Mini-Mental State
Examination.
*Selected reimbursement end points should be validated against desired
long-term outcomes.
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tical Research andManufacturers of America, between 1998
and 2011, only three new medicines were approved to treat
AD patients’ symptoms. During that same period, 101 med-
icines in development “failed”—that is, they were either dis-
continued or rendered inactive [22]. Recent late-stage
clinical trial failures have suggested the need to treat AD pa-
tients before they sustain irreversible damage and the need to
consider combination therapies designed to halt disease pro-
gression by targeting multiple pathways. However, even if a
developer could confidently turn its attention to asymptom-
atic patients, the necessary trials to demonstrate safety, effi-
cacy, and functional benefit for approval and reimbursement
would be prohibitively expensive because of the long natural
course of AD. It appears that developing AD treatments has
become too risky under conventional business models. To re-
invigorate development programs, stakeholders should
explore new business models and align earlier on pre- and
postlaunch evidentiary requirements.
Interventions to improve nutrition and lifestyle are help-
ful, and investments are needed to study their potential to
reduce overall risk to society. However, we do not believe
that these risk-reducing strategies will prevent all persons
from developing AD. Therefore, continued investment in
drug discovery is also critical. Stakeholders should begin
to pilot new development models and agreements that recog-
nize the complexities of development and measuring AD
outcomes. To lessen the massive cost and mitigate some of
the risk of conducting AD trials, some form of public-
private collaboration among industry, regulators, and payers
is necessary. The ADWG discussed both regulatory andreimbursement approaches as vehicles for managing the un-
certainty of developing new medicines for AD, including
conditional approval, adaptive licensing, managed entry,
conditional reimbursement, and risk-sharing agreements.
Alternatively, if the focus on AD treatments moves to
prevention, AD innovation could be bolstered by a
vaccine-like procurement model that is more in line with a
low-margin high-volume market.
Days after the last ADWG meeting, on February 7, 2013,
the US Food and Drug Administration issued new draft guid-
ance on developing drugs for early stage AD, recognizing
the need for new approaches to trial design and end point se-
lection [23]. In a separate perspective, the authors of the US
draft guidance described the extreme difficulty in assessing
functional impairment in the earliest stages of AD (i.e., pre-
clinical AD) and explained how the draft guidance provides
a pathway for accelerated approval in this early stage popu-
lation on the assessment of a cognitive outcome alone [24].
In such a scenario, a novel drug could be approved on a sin-
gle cognitive end point, provided that the developer agrees to
conduct postapproval studies to demonstrate a more com-
plete picture of the clinical benefit. The European regulatory
point of view, as shared by the Italian regulators, is slightly
different in that a single primary cognitive end point would
not be sufficient for conditional approval in the preclinical
AD context. However, they voiced a similar strategy for
demonstrating clinical efficacy in prodromal AD/MCI due
to AD. Assuming that continuity exists between prodromal
AD/MCI due to AD and overt AD dementia, efficacy for a
drug that delays disease progression should be demonstrated
in two trials. First, in a trial of prodromal AD/MCI patients
with virtually no functional impairment at baseline, efficacy
should be demonstrated on a composite end point such as the
Clinical Dementia Rating scale Sum of Boxes. Second, in a
mild AD dementia population, two coprimary end points ad-
dressing both cognition and function would be necessary. In
this context, EMAwould value a comprehensive assessment
of efficacy including evidence from secondary end points
and biomarkers in addition to clinical relevance from pri-
mary end points.
In addition to licensing collaboration, stakeholders need
to align on postlaunch evidentiary requirements for AD
medicines earlier in their development time frame. A greater
emphasis on real-world effectiveness in postlaunch studies
would help to bridge the gap between regulatory and reim-
bursement requirements. Such studies would allow all stake-
holders to appreciate whether a new drug is a significant or
merely incremental improvement.
For strategies such as conditional reimbursement to be
most effective, stakeholders should agree before launch on
the launch and postlaunch evidence needed to demonstrate
efficacy and value. Additionally, any successful variation
on this theme likely would require the coordinated involve-
ment of HTAs across multiple countries to lower the costs of
postlaunch data collection. Through conditional reimburse-
ment, health authorities would be making an investment in
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burden on developers of generating the necessary effective-
ness data. This approach facilitates the introduction of new
medicines and provides health systems the ability to value
and deploy those medicines more precisely. Although the
validity and credibility of postlaunch pragmatic data may
not be as robust as randomized controlled trial data, the po-
wer of large-scale real-world data may provide insight into
the value of treatments despite current deficits in scientific
understanding. We believe that industry, regulators, and
HTAs should look for an opportunity to pilot this model
with a novel medicine as soon as possible.
4. Conclusion
Scientists have proven AD to be incredibly complex, and
so a “magic bullet” treatment remains elusive. Attention and
resources must be properly allocated between improving the
present quality of care and developing future treatments.
Coming out of the focused engagement of the ADWG, we
recognize that all stakeholders, including patients and their
families, must increasingly work together to develop new
paradigms that acknowledge the particular strengths and
resource limitations of each stakeholder. Together, our five
recommendations dictate that courageous leadership,
collaboration, and creativity are needed to decipher the com-
plex biological underpinnings of AD, sustainably manage
the short- and long-term costs of patient care, and, most
importantly, meet the needs of patients and their carers today
and in the future.
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